Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kukjeon Pharmaceutical Co., Ltd. (307750:KRX), powered by AI.
Kukjeon Pharmaceutical Co., Ltd. is currently trading at ₩2,555. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kukjeon Pharmaceutical Co., Ltd. on Alpha Lenz.
Kukjeon Pharmaceutical Co., Ltd.'s P/E ratio is -32.1.
“Kukjeon Pharmaceutical Co., Ltd. trades at a P/E of -32.1 (undervalued) with modest ROE of -4.4%.”
Ask for details →Kukjeon Pharmaceutical Co., Ltd. is a prominent player in the biotechnology and pharmaceutical industry, primarily focusing on the research, development, and manufacturing of innovative medical products. The company's core mission is to enhance health and well-being through cutting-edge medical solutions. It specializes in a wide range of pharmaceutical products, including patented drugs, generics, and over-the-counter medications that cater to various therapeutic areas such as cardiovascular health, oncology, and infectious diseases. Kukjeon Pharmaceutical places a strong emphasis on quality, safety, and efficacy, adhering to stringent regulatory standards. Its operations significantly impact the healthcare sector, supporting medical advancements and addressing unmet medical needs. As it expands its portfolio and global reach, Kukjeon Pharmaceutical Co., Ltd. plays a crucial role in the advancement of pharmaceutical sciences and contributes to improving patient outcomes across diverse markets.
“Kukjeon Pharmaceutical Co., Ltd. trades at a P/E of -32.1 (undervalued) with modest ROE of -4.4%.”
Ask for details →Kukjeon Pharmaceutical Co., Ltd. (ticker: 307750) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - General). It has approximately 172 employees. Market cap is $137.9B.
The current price is ₩2,555 with a P/E ratio of -32.09x and P/B of 1.43x.
ROE is -4.44% and operating margin is -1.97%. Annual revenue is $131.0B.